|
|
 |
 |
 Printable version |
Le myélome multiple
Multiple myeloma
|
|
|
|
L’Intergroupe francophone du myélome (IFM)
2010
Series : Collection FMC de la revue Hématologie
Find out the books of Collection FMC de la revue Hématologie
ISBN : 978-2-7420-0668-7
72 pages
Specialty : Oncology, Hematology, Oncology
Published in : French
|
Price :
25.00 € |
 Add to shopping cart
| One-click order
|
|
|
Book written in french
The treatment of multiple myeloma has changed radically as a result of the recent introduction of a variety of molecules (thalidomide, bortezomib
and lenalidomide) which offer new therapeutic alternatives for patients of all ages. In addition, the new genetic methods have led to fundamental changes in the classic prognostic factors.
These clinical and biological breakthroughs have been greeted with great enthusiasm by international research teams. It may soon be possible to adapt treatment to a predictable prognosis or specific markers… The clinical research sector has followed the example of the French language myeloma intergroup (IFM), to which the authors of this book belong…
and there is now strong competition to define the optimal uses of the currently available treatments and to evaluate novel agents.
Can we cure myeloma? If so, which cases? With what treatments? Or should we treat myeloma as a chronic condition?
Intended for hematologists, biologists, pharmacists and interns, this book described the international consensus reached in 2009 concerning the management of myeloma patients: pathophysiology, prognostic factors, diagnosis, classification and treatment.
CONTENTS
- Preface
J.-L. Harousseau
- Background, incidence and clinical aspects of multiple myeloma
S. Le Gouill
- Biological prognostic factors for myeloma: role of cytogenetics?
H. Avet-Loiseau
- Treating young patients with myeloma
P. Moreau, T. Gastinne, N. Blin,
M. Attal, J.-L. Harousseau
- First line treatment of elderly patients with multiple myeloma who are not suitable candidates for an autologous stem cell transplant
L. Pascal, H. Debarri, M. Wemeau, S. Balkaran, B. Des Champs-Bro, B. Thielemans, T. Facon, X. Leleu
- New medicines for myeloma
C. Hulin, C. Touzeau, P. Moreau
- New recommendations issued by the Washington International Myeloma Workshop
H. Avet-Loiseau
- Anemia and myeloma
P. Moreau
|
|
